Newron's Evenamide: Safety Clearance, FDA Snag, and a Stock Caught Between Two Time Frames

FDA maintains clinical hold on Newron's schizophrenia drug Evenamide after independent safety board cleared it of patient death link, leaving stock torn between long-term promise and near-term pressure.

A safety board has cleared Newron’s schizophrenia drug candidate Evenamide of any connection to a patient death, yet the US clinical hold remains in force — a contradiction that encapsulates the stock’s current tug-of-war between long-term promise and acute near-term pressure. Shares closed Friday at €15.25, down 0.33% on the session, but the bigger story is the split-screen performance: a 90.86% gain over twelve months from last June’s trough of €7.11, versus a 42.67% year-to-date slide that has pulled the stock 53.72% below its 52-week high of €32.95 reached in January.

The FDA suspended enrolment at US sites for the ENIGMA-TRS-2 study in late April after a patient death outside the United States. An independent international safety committee subsequently concluded the death was unrelated to the treatment and recommended that the trial continue as planned. That exoneration, however, has not prompted the agency to lift the pause, leaving Newron unable to recruit new US subjects for the second of its two phase III programmes. The first study, ENIGMA-TRS-1, continues to enrol patients in Europe, Asia and Latin America, preventing a complete clinical stall.

The technical backdrop underscores the tension. At €15.25, the stock trades below both its 50-day moving average of €16.46 and its 200-day moving average of €18.03 — a classic bearish configuration. The relative strength index at roughly 56 points to neutral territory, offering no clear oversold or overbought signal, while the annualised thirty-day volatility of around 76% reflects the jittery hand-to-hand trading typical of a small-cap biotech in a data-dependent phase.

Newron’s financial footing, at least, provides some cushion. A €15 million capital increase in February plus a further €11 million expected from a financing agreement sometime in 2026 are projected to cover operating costs and clinical programmes well into 2027. Additional liquidity comes from licensing payments tied to Xadago, the marketed Parkinson’s drug based on safinamide. The company also refreshed its board in late April, with shareholders electing George Garibaldi and Paolo Zocchi as independent non-executive directors, replacing Patrick Langlois and Luca Benatti after their lengthy tenures.

The immediate catalysts are a health conference in June 2026 and first-half results due in September, where management is expected to update the phase III timeline and refine the funding outlook. The harder milestone comes in the fourth quarter of 2026, when Newron plans to release the primary twelve-week efficacy data from ENIGMA-TRS-1. Until then, the stock is likely to remain a prisoner of clinical uncertainty — reassured by safety signals but unable to break free until the efficacy readout offers a firmer direction for Evenamide’s journey toward approval.